Langerhans cell histiocytosis natural history: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Langerhans cell histiocytosis}}
{{Langerhans cell histiocytosis}}
{{CMG}}


Please help WikiDoc by adding content here.  It's easy!  Click  [[Help:How_to_Edit_a_Page|here]]  to learn about editing.
Please help WikiDoc by adding content here.  It's easy!  Click  [[Help:How_to_Edit_a_Page|here]]  to learn about editing.

Revision as of 19:36, 13 September 2012

Langerhans cell histiocytosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Langerhans cell histiocytosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Langerhans cell histiocytosis natural history On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Langerhans cell histiocytosis natural history

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Langerhans cell histiocytosis natural history

on Langerhans cell histiocytosis natural history

Langerhans cell histiocytosis natural history in the news

Blogs on Langerhans cell histiocytosis natural history

Directions to Hospitals Treating Langerhans cell histiocytosis

Risk calculators and risk factors for Langerhans cell histiocytosis natural history

Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.

Overview

Prognosis

Excellent for single foci disease.
With multi-focal disease 60% have a chronic course, 30% achieve remission and mortality is up to 10%[1].

References

  1. Komp D, El Mahdi A, Starling K, Easley J, Vietti T, Berry D, George S (1980). "Quality of survival in histiocytosis X: a Southwest Oncology Group study". Med. Pediatr. Oncol. 8 (1): 35–40. PMID 6969347.


Template:WikiDoc Sources